Montagu Private Equity (“Montagu”) and Astorg Partners (“Astorg”) today announce that they have entered into final exclusive negotiations with respect to the sale of their remaining majority stake in Sebia, a world leading manufacturer of instruments and reagents for in-vitro diagnostics, to CVC Capital Partners Strategic Opportunities (“CVC”) and Téthys Invest.
After the partial sale to Caisse de Dépôt et Placement du Québec (“CDPQ”) announced in August 2017, this transaction would complete Astorg’s and Montagu’s exit from Sebia. CVC and Téthys Invest would therefore join CDPQ and the company’s management as shareholders of Sebia.
Founded in 1967, Sebia is a world’s leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostic testing. Its systems analyse proteins in order to screen and monitor various diseases and conditions; primarily oncology (multiple myeloma), metabolic disorders such as diabetes and also hemoglobinopathy and rare pathologies. The company is headquartered in Lisses, France, and operates across more than 120 countries.
Over the past three years, Montagu and Astorg have supported management’s strategy, which has allowed Sebia to develop significantly in the global myeloma diagnosis market, successfully penetrate the diabetes market, reinforce its presence in certain export markets by acquiring the Italian company Interlab, and announce its entry into the free light chain market.
Benoît Adelus, Chairman of Sebia, said: “I would like to thank both Astorg and Montagu teams for their strong support over the past three years. We welcome CVC and Téthys Invest as new shareholders of Sebia. Together with CDPQ and management, our new shareholders support our strategy and growth plans with a long term view. We look forward to reinforcing Sebia’s franchise and expand its product and geographical footprint.”
The contemplated transaction remains subject to workers’ council information and consultation and to the approval of relevant regulatory authorities. The terms of the transaction were not disclosed.
Montagu UK Andrew Honnor, Alex Jones and Ryan Smith Greenbrook Communications +44 207 952 2000
France Image 7 Anne-France Malrieu / Caroline Simon firstname.lastname@example.org +33 (1) 53 70 74 66
Publicis Consultants Ségolène de Saint Martin email@example.com +33 6 16 40 90 73
Notes to Editors
About Montagu Private Equity
Montagu Private Equity is one of Europe’s leading private equity firms. Founded in 1968, Montagu can look back on more than 45 years’ experience in investing in more than 400 transactions. Montagu has a strong track record of supporting portfolio companies, dedicating significant resource to management teams as well as providing additional capital expenditure to fund further growth. Montagu also has considerable expertise helping businesses to accelerate their growth in their home markets as well as to internationalise and expand their customer base. This approach has led to real growth across Montagu’s portfolio. The firm currently has assets under management of just over €5 billion. Montagu invests in businesses that operate in stable markets across Europe with transaction values ranging from approximately €100 million to €1 billion. www.montagu.com
About Astorg Partners
Astorg is a European private equity firm with total funds under management of over €4 billion. Astorg seeks to partner with entrepreneurial management teams to acquire European companies and create value through the provision of strategic guidance, experienced governance and adequate capital. Astorg enjoys a distinct entrepreneurial culture, a long-term shareholder perspective, and a lean decision-making body enhancing its reactivity. Though not specialized, Astorg has gathered a valuable industry expertise in technology-based industrial companies, healthcare and business-to-business professional services. Astorg has offices in London, Paris and Luxembourg, plus Senior Advisors based in Zurich and Frankfurt. www.astorg.com
SEBIA is a world’s leading provider of clinical protein electrophoresis equipment and reagents, a technology used for in-vitro diagnostics (IVD) testing. Its systems analyse proteins in order to screen and monitor various diseases and conditions, primarily myeloma (a non-curable but partially treatable blood cancer, which typically affects people over 50 years old), genetic haemoglobin disorders, and diabetes (with its HbA1c test). The company's head office and research and production facilities are located in Lisses, near Paris. Sebia has 530 employees worldwide and generates more than three quarters of its revenues outside of France. www.sebia.com